| pubmed-article:8512591 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8512591 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:8512591 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8512591 | lifeskim:mentions | umls-concept:C0027468 | lld:lifeskim |
| pubmed-article:8512591 | lifeskim:mentions | umls-concept:C0600251 | lld:lifeskim |
| pubmed-article:8512591 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:8512591 | lifeskim:mentions | umls-concept:C1518174 | lld:lifeskim |
| pubmed-article:8512591 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:8512591 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8512591 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:8512591 | pubmed:dateCreated | 1993-7-9 | lld:pubmed |
| pubmed-article:8512591 | pubmed:abstractText | Interleukin-1 alpha (IL-1 alpha) exerts antiproliferative effects on a human ovarian carcinoma cell line, NIH:OVCAR-3, which is resistant to clinically relevant concentrations of doxorubicin (DOX) and other chemotherapeutic agents. This action of IL-1 alpha depends on the presence of type I (80 kDa) receptors, although no quantitative relationship has been established between receptor occupancy and inhibition of cell growth. When NIH:OVCAR-3 cells were exposed to IL-1 alpha and DOX in combination, a mutual potentiation of the antiproliferative effects of the two agents was observed. This synergistic effect was not due to IL-1 receptor expression up-regulation by DOX, and receptor-dependent internalization of the cytokine was also unaffected. The involvement of IL-1 receptors is supported by the observation that synergism between the two agents was diminished (but not abolished) in the presence of a specific IL-1 receptor antagonist at concentrations blocking more than 75% of IL-1 alpha binding. DOX was found to significantly increase IL-1 alpha accumulation by NIH:OVCAR-3 cells after long-term (48 hr) exposure to the cytokine at 37 degrees, which might be due to increased nonspecific fluid phase uptake or to interference with cytokine degradation and/or release processes. The potent synergy of IL-1 alpha and DOX against ovarian carcinoma cells in vitro suggests that this drug combination may be effective against this disease in the clinic. | lld:pubmed |
| pubmed-article:8512591 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8512591 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8512591 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8512591 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8512591 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8512591 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8512591 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8512591 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8512591 | pubmed:month | May | lld:pubmed |
| pubmed-article:8512591 | pubmed:issn | 0006-2952 | lld:pubmed |
| pubmed-article:8512591 | pubmed:author | pubmed-author:MimnaughE GEG | lld:pubmed |
| pubmed-article:8512591 | pubmed:author | pubmed-author:SinhaB KBK | lld:pubmed |
| pubmed-article:8512591 | pubmed:author | pubmed-author:MontiEE | lld:pubmed |
| pubmed-article:8512591 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8512591 | pubmed:day | 25 | lld:pubmed |
| pubmed-article:8512591 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:8512591 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8512591 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8512591 | pubmed:pagination | 2099-107 | lld:pubmed |
| pubmed-article:8512591 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:meshHeading | pubmed-meshheading:8512591-... | lld:pubmed |
| pubmed-article:8512591 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8512591 | pubmed:articleTitle | Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3). | lld:pubmed |
| pubmed-article:8512591 | pubmed:affiliation | Biochemical and Molecular Pharmacology Section, National Cancer Institute, NIH, Bethesda, MD 20892. | lld:pubmed |
| pubmed-article:8512591 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8512591 | lld:pubmed |
